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Background: Comparative survival data on patients with mitral regurgitation (MR) at high surgical risk treated with transcatheter devices targeting 
MR reduction is limited. We compared survival among high risk MR patients treated with the MitraClip to matched non-surgically treated patients 
from the Duke Echocardiography Laboratory Database (DELD).
Methods: High risk patients with 3+/4+ MR managed non-surgically between the years 2000-10 in the longitudinal DELD were subset for matching 
to MitraClip High Risk patients. Patient matching was performed using the method of nearest available Mahalanobis distance metric within calipers 
defined by the propensity score. Kaplan-Meier analyses and stratified Cox proportional hazards models were used to compare survival at 30 days 
and 1 year. These outcomes were also analyzed in functional MR (FMR) subgroup from the matched cohort.
Results: Among 953 high risk patients in the DELD available for matching, mortality at 30 days and 1 year was 6.5% and 26.2% respectively. 
Matches were obtained for 127 of the 211 MitraClip patients. There were no statistically significant differences in baseline and demographic 
characteristics between the matched groups except for significantly larger left ventricular end-systolic diameter (LVESD) in MitraClip patients. The 
30-day mortality in MitraClip patients was similar to that seen in matched DELD patients (p=0.64). Matched patients from the DELD had a 42% 
increase in the risk of all-cause mortality at 1 year compared to MitraClip patients (HR =1.42, 95% CI 0.86 - 2.35; log rank p=0.169). After adjusting 
for baseline differences in LVESD, the MitraClip effect approached statistical significance (p=0.056). Among the FMR matched subgroup, in the 
adjusted analysis, the hazard of all-cause mortality at 1 year in the DELD was twice that of MitraClip patients (p=0.022).
Conclusions: This unique matched comparison of severe MR patients at high surgical risk suggests a likelihood of a mortality benefit at 1 year for 
the MitraClip particularly among patients with functional MR.
